Skip To Content
Bradley White | Intellectual Property Litigation Lawyer

J. Bradley White

Partner, Intellectual Property

Chair: Intellectual Property Litigation


Contact Information

bwhite@osler.com

tel: 613.787.1101

Office

Ottawa

Bar Admission

Ontario, 1998

Education
  • University of Windsor, LL.B.
  • University of Waterloo, M.Sc.
  • University of Western Ontario, B.Sc.
Language(s)
English

A partner, Brad practises complex patent litigation, including pharmaceutical proceedings under PM (NOC) Regulations. Provides strategic advice on the enforcement of patent rights and coordination and management of litigation strategies throughout multiple jurisdictions. Appeared as lead counsel before the Federal Court of Appeal, Federal Court, Ontario Superior Court and as worldwide coordinating litigation and IP counsel before the US International Trade Commission. A Registered Patent Agent, he specialises in Canadian and foreign patent and industrial design prosecution, strategic IP portfolio reviews, patentability, patent infringement and validity opinions, worldwide patent portfolio management and enforcement advice. Registered to practise before the USPTO and is a past associate editor of the Canadian Patent Reporter. Rankings include: The Canadian Legal Lexpert® Directory 2019: Intellectual Property, Litigation (Intellectual Property), Biotechnology; Lexpert® US/Canada Cross-Border Guide 2017: Litigation; Best Lawyers in Canada 2019: Intellectual Property Law; Chambers Global 2019: Intellectual Property Litigation (Canada); IAM Patent 1000 2019: Strategy 300; Managing IP 2018-2019: Patent Star Canada; Benchmark Litigation 2019: Litigation Star; Acritas Star Lawyer (2019) and Who’s Who Legal 2019 (Life Sciences, Patents, Patent Litigation).

    Mylan Pharmaceuticals ULC:

    Lead outside counsel to Mylan Pharmaceuticals ULC in patent litigation, prosecution and other matters. Presently representing or successfully settled numerous complex pharmaceutical litigation matters on behalf of Mylan in relation to products seeking market entry including TECTA® (Pantoprazole Mg), CIALIS® (Tadalafil), SENSIPAR® (Cinacalcet) and VIMOVO® (Naproxen and esomeprazole Mg).

    Amgen Inc et. al. v BHP Pharma ULC dba Mylan EPD T-420-19

    AstraZeneca Canada Inc. et al. v Mylan Pharmaceuticals ULC et al. T-336-15 (2017), T-184-19

    Eli Lilly et al. v. Mylan Pharmaceuticals ULC T-1627-16

    Takeda Pharmaceuticals et al. v. Mylan Pharmaceuticals ULC et al. T-1161-13 (2015) FC 751

    Takeda Pharmaceuticals et al. v. Mylan Pharmaceuticals ULC et al. T-1451-11 (2015)

    Amgen Canada Inc. v Mylan Pharmaceuticals ULC et al. T-2056-14 (2015)

    Amgen Canada Inc. v. Mylan Pharmaceuticals ULC et al T-1584-17

    (Federal Court File No. T-1584-17) SENSIPAR (Cinacalcet) Section 8 Damages

    Novartis Pharmaceuticals v Mylan Pharmaceuticals ULC et al. T-365-14 (2014)

    AstraZeneca et al. v Mylan Pharmaceuticals ULC et al. 2011 FC 312, 2012 FCA 109

    Pfizer Canada Inc et al. v Mylan Pharmaceuticals ULC et al. 2011 FC 547; 2012 FCA 103

    Janssen Inc. v Mylan Pharmaceuticals ULC et al. T-1577-14 (2011)

    Sanofi-Aventis v Mylan Pharmaceuticals ULC et al. T-1441-12 (2010)

    Lundbeck Canada Inc. v Mylan Pharmaceuticals ULC et al. (2009) 73 C.P.R. (4th) 69 (F.C.T.D.); (2010) 88 C.P.R. (4th) 325 (F.C.A.), SCC 34068

     

    Teva Canada Limited:

    Lead outside counsel to Teva Canada Limited in patent litigation, prosecution and other matters. Presently representing or successfully settled complex pharmaceutical and general litigation matters on behalf of Teva including in relation to CUBICIN® (Daptomycin), SPRYCEL® (Dasatinib Monohydrate) and VICTOZA® (Liraglutide).

    Bristol-Myers Squibb Canada Co v. Teva Canada Limited T-1774-18

    Bayer Inc. and Bayer Intellectual Property GMBH v. Teva Canada Limited T-1960-18, T-1021-19.

    Bayer Inc. et al v. Teva Canada Limited T-1692-18

    Novo Nordisk Canada Inc. v. Teva Canada Ltd. et al. T-727-18, T-65-19

     

    Teva/Celltrion Healthcare:

    Lead outside counsel to Teva/Celltrion in complex pharmaceutical litigation matters including the biosimilars to RITUXAN® (Rituximab) and HERCEPTIN® (Trastuzumab).

    F. Hoffmann-La Roche Limited v. Celltrion et al. T-1486-17, T-1487-17, T-1488-17, T-1489-17

    Genentech, Inc. et al. v. Celltrion Healthcare Co., Ltd. T-1969-17, T-1970-17, T-1971-17

     

    Samsung Bioepis:

    Representing Samsung Bioepis in several significant patent litigation cases, including the first case brought in Canada under the Patented Medicines (Notice of Compliance) Regulations in relation to blockbuster biopharmaceutical ENBREL® (etanercept). Also represented Samsung in patent litigation proceedings relation to the world’s biggest drug HUMIRA® (adalimumab).

    Abbvie Biotechnology et al v. Samsung Bioepis Co., Ltd. and the Minister of Health T-598-17, T-599-17, T-600-17, T-601-17, T-602-17, T-603-17, T-604-17, T-605-17

    Amgen Canada Inc. and Immunex Corporation v. Samsung Bioepis Co., Ltd. and the Minister of Health T-1283-15 (2014)

     

    Standard Innovation Corporation:

    Representing Standard Innovation Corporation (now WOW Tech) in the role of world-wide coordinating litigation and IP counsel, including the following cases:

    Opposition Proceedings in respect of European Patent No. EP 1 824 440 in the European Patent Office

    Appeal from the US International Trade Commission, Investigation No. 337-TA-823, United States Court of Appeals for the Federal Circuit, No. 2013-1582, Lelo Inc. & Leloi AB v. International Trade Commission and Standard Innovation (US) Corp. & Standard Innovation Corporation

    District Court Action before the United States District Court of Northern California  5:13-cv-01393-PSG: Lelo Inc v. Standard Innovation (US) Corp and Standard Innovation Corporation

    Ex Parte reexamination of the United States Patent No. 7,931,605 (“the ‘605 Patent”)

    Lead Canadian IP  counsel to Standard Innovation Corporation including in T-925-12: Standard Innovation Corporation  v. Lelo AB et Lelo Inc., 1531011 Ontario Inc., Cana International Distributing Inc., Landco Import International Inc. and TBMBM Inc.

    Two Inter Partes Review Re: Standard Innovation Corporation (Petitioner) v. Lelo Inc. [Patent Owner; Cases IPR 2014-00148 and IPR 2014-00907, Re: United States Patent No. 7,749,178 (“the ‘178 Patent”)].

     

    ratiopharm Inc:

    Abbott Laboratories v. ratiopharm Inc. et al. (2004), 31 C.P.R. (4th) 321 (F.C.A.)

    Abbott Laboratories v. ratiopharm Inc. et al. (2005), 42 C.P.R. (4th) 20 and 121 (F.C.T.D.)

    Abbott Laboratories v. ratiopharm Inc. et al. (2005) 34 C.P.R. (4th) 468 (F.C.T.D.)

     

    Novopharm Ltd:

    Janssen-Ortho Inc. and Daiichi Pharmaceutical Co, Ltd. v. Novopharm Ltd. et al. 2006 FC 1333, (2006) 57 C.P.R. (4th) 6 and 58 (F.C.T.D.)

    Janssen-Ortho Inc. v. Novopharm Ltd. et al. (2005), 39 C.P.R. (4th) 197 (F.C.A.)

    Janssen-Ortho Inc. v. Novopharm Ltd. et al. (2005), 35 C.P.R (4th) 353 (F.C.T.D.), appeal dismissed (2005), 40 C.P.R. (4TH) 1 (F.C.A.)

     

    Other:

    Acting as counsel to Munchkin Baby Canada, Ltd. and its U.S. affiliate in the defence of a Federal Court patent infringement action relating to the defendants’ making and selling of cartridges for diaper pails. Angelcare Development Inc. et al. v. Munchkin, Inc et al  T-151-16

    Counsel to Skretting Canada Inc. in letters rogatory proceedings relating a US patent dispute concerning methods for raising fish. Marical, Inc. v. Skretting Canada Inc. SJM-51-2016

    Nycomed v. Genpharm ULC et al. 2008 FC 330, (2008), 64 C.P.R. (4th) 388 (F.C.T.D.)

  • Chambers: Ranked in Chambers Canada: Canada’s Leading Lawyers for Business: Intellectual Property: Litigation - Band 1 and Life Sciences: IP/Patent Litigation - Spotlight Table; Chambers Global: The World’s Leading Lawyers for Business: Intellectual Property Litigation and Intellectual Property
    • The "very practical" Bradley White is appreciated by clients as an adviser who "cuts to the chase quickly and tells us things straight." He is the lead partner advising Mylan Pharmaceuticals regarding its Canadian patent litigation claims, as well as a number of class action and other cases in which it is involved.
  • Lexpert: Ranked in The Canadian Legal Lexpert Directory: Intellectual Property; Biotechnology and Litigation – Intellectual Property; Ranked in Lexpert Guide to the Leading US/Canada Cross-Border Litigation Lawyers: Canadian Litigation Lawyer to Watch
  • Benchmark Litigation: Ranked in Benchmark Litigation Canada: "Litigation Star", Intellectual Property
  • Who’s Who Legal: Ranked in Who's Who Legal: International - Life Sciences - Patent Litigation and Patents; Ranked in Who's Who Legal: Canada - Life Sciences
  • Best Lawyers: Ranked in Best Lawyers in Canada: Intellectual Property Law
  • Intellectual Asset Magazine: Ranked in IAM Strategy 300: The World’s Leading IP Strategists; Ranked in Intellectual Asset Magazine (IAM) Patent 1000: World's Leading Patent Professionals: One of the World’s Leading Patent Litigators and Prosecutors; Ranked in International Asset Magazine (IAM) Life Science 250: One of the World’s Leading Life Sciences Litigators
  • Managing IP: Ranked in Managing IP (Canada): IP Star, Patent, Copyright
  • Legal 500: Ranked in The Legal 500: Leading Lawyer, Intellectual Property
  • Euromoney LMG: Ranked in Euromoney LMG's Life Sciences Publication: Intellectual Property
  • Acritas Stars: Recognized as a Star Lawyer

  • Royal Ottawa Golf Club, Past Board Member (3 years service)

  • Intellectual Property Institute of Canada
  • American Intellectual Property Law Association
  • International Association for the Protection of Intellectual Property (AIPPI)
  • Canadian Bar Association

Scientific Publications

  • Co-author of the Canadian Intellectual Property Guide 2018 published by the Chinese National Intellectual Property Administration (CNIPA - formerly SIPO).
  • J.B.White, M.Dulick and P.F. Bernath, The High Resolution Infrared Emission Spectra of InH and InD, J. Mol. Spec., 169, 410-420 (1995).
  • T. Karkanis, Z. Morbi, J.B. White, M. Dulick and P.F. Bernath, The High Resolution Infrared Emission Spectrum of InF, Canadian J. Phys., 72, 1213-1217 (1994).
  • R. LeBlanc, J.B. White and P,F. Bernath, Improved Rotational Constants far HCI and HF, J, Mol, Spec., 164, 574 (1994).
  • J.B. White, M,Dulick and P.F. Bernath, The High Resolution Infrared Emission Spectra of AIH and AID J. Chem. Phys., 99, 8371 (Dec. 1993).
  • J.Campbell, M.Dulick, D.Klapstein, J.B. White and P.F.Bernath, The High Resolution Infrared Emission Spectra of GaH and GaD, J Chem. Phys., 99, 8379 (Dec. 1993).

Other Publications

  • Key issues for senior life sciences executives, IP in the Life Sciences Industries 2014 (This article first appeared in Intellectual Asset Management issue 66, published by The IP Media Group. To view the report in full, go to www.iam-magazine.com)